Summary
Local perfusion with ibogaine (10−6M—10−3M) via microdialysis probes in the nucleus accumbens or striatum of rats produced a biphasic dose-response effect on extracellular dopamine levels. Lower doses (10−6M—10−4M) produced a decrease while higher doses (5 × 10−4M—10−3M) produced an increase in dopamine levels. Dihydroxyphenylacetic acid (DOPAC) levels were not effected. Naloxone (10−6M) and norbinaltorphimine (10−6M—10−5M) did not affect dopamine levels, but when co-administered with ibogaine (10−4M) blocked the decrease in dopamine levels produced by ibogaine. Ibogaine (10−3M) stimulation of dopamine levels in the striatum was calcium independent and not blocked by tetrodotoxin (10−5M). Pretreatment with cocaine (15mg/kg), reserpine (5mg/kg) or alpha-methyl-paratyrosine (250mg/kg) given intraperitoneally significantly reduced ibogaine (10−3M) stimulation of striatal dopamine levels. In striatal synaptosomes, both ibogaine and harmaline (10−7—10−4M) produced dose-dependent inhibition of [3H]-dopamine uptake. These findings suggest that ibogaine has both inhibitory and stimulatory effects on dopamine release at the level of the nerve terminal. It is suggested that the inhibitory effect is mediated by kappa opiate receptors while the stimulatory effect is mediated by interaction with the dopamine uptake transporter.
Similar content being viewed by others
References
Alexander GM, Grothusen JR, Schwartzman RJ (1988) Flow dependent changes in the effective surface area of microdialyis probes. Life Sci 43: 595–601
Bogdanski DF, Brodie BB (1969) The effects of inorganic ions on the storage and uptake H3-norepinephrine by rat heart slices. J Pharmacol Exp Ther 165: 181–189
Broderick PA (1987) Striatal neurochemistry of Dynorphin-(1-13): in vivo electrochemical semi-differential analysis. Neuropeptides 10: 369–386
Broderick PA, Phelan FT, Eng F, Wechsler RT (1994) Ibogaine modulates cocaine responses which are altered due to environmental habituation: in vivo microvoltammetric and behavioral studies. Pharmacol Biochem Behav 49: 711–728
Cappendijk SLT, Dzoljic MR (1993) Inhibitory effects of ibogaine on cocaine self-administration in rats. Eur J Pharmacol 241: 261–265
Carboni E, Imperato A, Perezanni L, DiChiara G (1991) Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats. Neuroscience 28: 653–661
Crawford CA, McDougall SA, Bolanos CA, Hall S, Berger SP (1995) The effects of the kappa agonist U-50,488 on cocaine-induced conditioned and unconditioned behaviors and Fos immunoreactivity. Psychopharm 120: 392–399
Deecher DC, Teitler M, Soderlund DM, Bornmann WG, Kuehne ME, Glick SD (1992) Mechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies. Brain Res 571: 242–247
Drucker G, Raikoff K, Neafsey NJ, Collins MA (1990) Dopamine uptake inhibitory capacities of beta-carboline and 3,4-dihydro-beta-carboline analogs of N-methyl-4-phenyl1,2,3,6-tetrahydropyridine (MPTP) oxidation products. Brain Res 509: 125–133
Fischer JF, Cho AK (1979) Chemical release of dopamine from caudate-putamen homogenate: evidence for an exhange diffusion model. J Pharmacol Exp Ther 208: 203–209
Florin SM, Kuczenski R, Segal DS (1995) Effects of reserpine on extracellular caudate dopamine and hippocampus norepinephrine responses to amphetamine and cocaine: mechanistic and behavioral consideration. J Pharmacol Exp Ther 274: 231–241
Fujise H, Hamada Y, Mori M, Ochiai H (1995) Na-dependent glutamate transport in high K and High glutathione (HK/HG) and high L low glutathione (HK/LG) dog red blood cells. Biochem Biophys Acta 1239: 22–26
Glick SD, Rossman K, Steindorf S, Maisonneuve IM, Carlson JN (1991) Effects and aftereffects of ibogaine on morphine self-administration in rats. Eur J Pharmacol 195: 341–345
Glick SD, Rossman K, Wang S, Dong N, Keller Jr RW (1993) Local effects of ibogaine on extracellular levels of dopamine and its metabolites in nucleus accumbens and striatum: interactions with d-amphetamine. Brain Res 628: 201–208
Harsing Jr LG, Sershen H, Lajtha A (1994) Evidence that ibogaine releases dopamine from the cytoplasmic pool in isolated mouse striatum. J Neural Transm [Gen Sect] 96: 215–225
Heidbreder CA, Goldberg SR, Shippenberg TS (1993) The kappa-opioid receptor agonist U-69593 attenuates cocaine-induced behavioral sensitization in the rat. Brain Res 616: 335–338
Hernandez L, Hoebel BG (1988) Food reward and cocaine increase extracellular dopamine in the nucleus accumbens as measured by in vivo microdialysis. Life Sci 42: 1,702–1,705
Hurd YL, Ungerstedt U (1989a) In vivo neurochemical profile of dopamine uptake inhibitors and releasers in rat caudate-putamen. Eur J Pharmacol 166: 251–260
Hurd YL, Ungerstedt U (1989b) Influence of a carrier transport process on in vivo release and metabolism of dopamine: dependence on extracellular Na+. Life Sci 45: 283–293
Janowsky A, Berger SP, Vocci F, Labarca R, Skolnick P, Paul SM (1986) Characterization of sodium dependent [3H]-GBR 12935 binding in brain: a radioligand for selection labeling of the dopamine transport complex. J Neurochem 46: 1,274–1,276
King SM, Tunnicliff G (1990) Na(+)- and Cl(−)-dependent [3H]GABA binding to catfish brain brain particles. Biochem Intl 20: 821–831
Kscha U, Farber SA, Marshall D, Wurtman RJ (1993) Carbachol and naloxone synergistically elevate dopamine release in rat striatum: an in vivo microdialysis study. Brain Res 613: 288–290
Lindefors N, Amberg G, Ungerstedt U (1989) Intracerbral microdialysis. I. Experimental studies of diffusion kinetics. J Pharmacol Meth 22: 141–156
Maisonneuve IM, Glick SD (1992) Interactions between ibogaine and cocaine in rats: in vivo microdialysis and motor behavior. Eur J Pharmacol 212: 263–266
Maisonneuve IM, Keller Jr RW, Glick SD (1991) Interactions between ibogaine, a potential anti-addictive agent, and morphine: an in vivo microdialysis study. Eur J Pharmacol 199: 35–42
Maisonneuve IM, Keller Jr RW, Glick SD (1992) Interactions of ibogaine and damphetamine: in vivo microdialysis and motor behavior in rats. Brain Res 579: 87–92
Maisonneuve IM, Archer S, Glick SD (1994) U50,488 a kappa opioid agonist attenuates cocaine induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci Lett 181: 57–60
Mash DC, Staley JK, Baumann MH, Rothman RB, Hearn WL (1995) Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin. Life Sci 57: PL45-PL50
McMillen BA, German DC, Shore PA (1980) Functional and pharmacological significance of brain dopamine and norepinephrine storage pools. Biochem Pharmacol 29: 3,045–3,050
Newman EA (1991) Sodium-bicarbonate cotransport in retinal Muller (glial) cells of the salamander. J Neurosci 11: 3,972–3,983
Osborne PG, O'Connor WT, Drew KL, Ungerstedt U (1990) An in vivo microdialysis characterization of extracellular dopamine and GABA in dorsolateral striatum of awake, freely moving and halothane anaesthetized rats. J Neurosci Meth 34: 99–105
Paton DM (1973) Mechanism of efflux of noradrenaline from adrenergic nerves in rabbit atria. Br J Pharmacol 49: 614–627
Pearl SM, Herrick-Davis K, Teitler M, Glick SD (1995) Radioligand binding study of noribogaine, a likely metabolite of ibogaine. Brain Res 675: 342–344
Popik P, Layer RT, Skolnick P (1994) The putative anti-addictive drug ibogaine is a competitive inhibitor of [3H]-MK-801 binding to the NMDA receptor complex. Psychopharm 114: 672–674
Sershen H, Hashim A, Harsing L, Abel L (1992) Ibogaine antagonizes cocaine-induced locomotor stimulation in mice. Life Sci 50: 1,079–1,086
Sershen H, Hashim, Lajtha A (1995) The effect of ibogaine on kappa-opioid and 5-HT3-induced changes in stimulation evoked dopamine release in vitro from striatum of C57BL/6By mice. Brain Res Bull 36: 587–591
Spanagel R, Herz A, Shippenberg TS (1990) The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J Neurochem 55: 1,734–1,740
Spanagel R, Herz A, Shippenberg TS (1992) Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci USA 89: 2,046–2,050
Spealman RD, Bergman J (1992) Modulation of the discriminative stimulus effects of cocaine by mu and kappa opioids. J Pharmacol Exp Ther 261: 607–615
Stahle L, Segersvard S, Ungerstedt U (1991) A comparison between three methods for estimation of extracellular concentrations of exongenous and endogenous compounds by microdialysis. J Pharmacol Meth 25: 41–52
Suzuki T, Shiozaki Y, Masukawa Y, Misawa M, Nagase H (1992) The role of mu- and kappa-opioid receptors in cocaine-induced conditioned place preference. Jpn J Pharmacol 58: 435–442
Sweetnam PM, Lancaster J, Snowman A, Collins JL, Perschke S, Bauer C, Ferkany J (1995) Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine's putative anti-addictive activity. Psychopharm 118: 369–376
Van Winkle LJ, Campione AL, Mann DF, Wasserlauf HG (1993) The cation receptor subsite of the choline transporter in preimplation mause conceptus resembles a cation receptor subsite of several amino acid transporters. Biochim Biophys Acta 1146: 38–44
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Reid, M.S., Hsu, K., Souza, K.H. et al. Neuropharmacological characterization of local ibogaine effects on dopamine release. J. Neural Transmission 103, 967–985 (1996). https://doi.org/10.1007/BF01291787
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01291787